Investigation of Regorafenib-induced Hypothyroidism in Patients with Metastatic Colorectal Cancer

Hypothyroidism is one of the side-effects caused by regorafenib. In the Japanese subset of the CORRECT study, hypothyroidism developed in 1.5% of the patients, but was not grade 3 or higher in any patient. Regorafenib is an oral multi-kinase inhibitor that has the same mechanism of action as sunitin...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 35; no. 7; pp. 4059 - 4062
Main Authors Sugita, Kazuo, Kawakami, Kazuyoshi, Yokokawa, Takashi, Mae, Yutaro, Toya, Wataru, Hagino, Akane, Suzuki, Kenichi, Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Yamaguchi, Toshiharu, Hama, Toshihiro
Format Journal Article
LanguageEnglish
Published Greece 01.07.2015
Subjects
Adult
Aged
Colorectal Neoplasms - drug therapy
Female
Humans
Hypothyroidism - chemically induced
Male
Middle Aged
Phenylurea Compounds - adverse effects
Phenylurea Compounds - therapeutic use
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
Pyridines - adverse effects
Pyridines - therapeutic use
Quality of Life
Thyroid Function Tests - methods
thyroid-stimulating hormone
metastatic colorectal cancer
regorafenib
hypothyroidism
Online AccessGet full text

Cover

More Information
Summary:Hypothyroidism is one of the side-effects caused by regorafenib. In the Japanese subset of the CORRECT study, hypothyroidism developed in 1.5% of the patients, but was not grade 3 or higher in any patient. Regorafenib is an oral multi-kinase inhibitor that has the same mechanism of action as sunitinb. However, the reported incidence of sunitinb-related hypothyroidism varies widely, ranging from 16.0% in clinical trials to 35.4% in post-marketing surveillance studies. In general, symptoms of hypothyroidism include fatigue and dysphonia. Hyperthyroidism must, therefore, be appropriately managed in order to maintain patient quality of life and avoid a critical level of hypothyroidism. During the first cycle of treatment with regorafenib, the incidence of abnormal thyroid-stimulating hormone (TSH) elevation was 31.4%. Our results suggest that thyroid function tests should be performed from day 1 of treatment with regorafenib. It would be prudent to consider routine monitoring of thyroid function in all patients who receive regorafenib and to recommend endocrinological consultation as necessary.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1791-7530